{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:13:39Z","timestamp":1788408819642,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00461-9","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:34:25Z","timestamp":1785465265000},"page":"515-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice"],"prefix":"10.1007","volume":"15","author":[{"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Obici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian aus dem","family":"Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Debonnaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"22","key":"461_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"461_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025;46(11):999\u20131013.","journal-title":"Eur Heart J"},{"issue":"1","key":"461_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326.","journal-title":"Circulation"},{"issue":"13","key":"461_CR4","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.3390\/jcm14134785","volume":"14","author":"C Tschope","year":"2025","unstructured":"Tschope C, Elsanhoury A, Kristen AV. Transthyretin amyloid cardiomyopathy-2025 update: current diagnostic approaches and emerging therapeutic options. J Clin Med. 2025;14(13):4785.","journal-title":"J Clin Med"},{"issue":"5","key":"461_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jacc.2025.09.013","volume":"87","author":"A Masri","year":"2026","unstructured":"Masri A, Judge DP, Ruberg FL, et al. Effect of acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM: exploratory analysis from ATTRibute-CM. J Am Coll Cardiol. 2026;87(5):490\u2013501.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"461_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146(22):1657\u201370.","journal-title":"Circulation"},{"issue":"1","key":"461_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","volume":"47","author":"M Fontana","year":"2025","unstructured":"Fontana M, Aimo A, Emdin M, et al. Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Eur Heart J. 2025;47(1):54\u201363.","journal-title":"Eur Heart J"},{"issue":"10","key":"461_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","volume":"85","author":"DP Judge","year":"2025","unstructured":"Judge DP, Alexander KM, Cappelli F, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2025;85(10):1003\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"461_CR9","unstructured":"European Medicines Agency. CHMP post-authorisation summary of positive opinion for Amvuttra (II-15). 2025. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-amvuttra-ii-15_en.pdf. Accessed 15 May 2026."},{"key":"461_CR10","unstructured":"European Medicines Agency. Orphan Maintenance Assessment Report: Vyndaqel (tafamidis). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report-post\/vyndaqel-orphan-maintenance-assessment-report-post-authorisation_en.pdf. Accessed Jan 30 2026."},{"key":"461_CR11","unstructured":"European Medicines Agency. BEYONTTRA: Summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyonttra-epar-product-information_en.pdf. Accessed 18 Mar 2026."},{"issue":"17","key":"461_CR12","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","volume":"61","author":"M Miller","year":"2018","unstructured":"Miller M, Pal A, Albusairi W, et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem. 2018;61(17):7862\u201376.","journal-title":"J Med Chem"},{"key":"461_CR13","unstructured":"US Food and Drug Administration. FDA approves Attruby\u2122 (acoramidis) for the treatment of ATTR-CM. U.S. Food and Drug Administration. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf. Accessed 19 June 2025."},{"key":"461_CR14","unstructured":"European Medicines Agency. Beyonttra: EPAR \u2013 public assessment report. European Medicines Agency. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyonttra. Accessed June 19 2025."},{"key":"461_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency. Beyonttra (acoramidis) Japanese prescribing information. 2025. https:\/\/www.pmda.go.jp\/files\/000278404.pdf. Accessed Mar 18 2026."},{"key":"461_CR16","unstructured":"Medicines & Healthcare Products Regulatory Agency. BEYONTTRA: Summary of product characteristics. 2025. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/25c5e2e489611ea7419717129979e3f550917093. Accessed 18 Mar 2026."},{"key":"461_CR17","unstructured":"Swissmedic. BEYONTTRA\u00ae, film-coated tablets (acoramidisum). Swissmedic. 2025. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/beyonttra-filmtabletten-acoramidisum.html. Accessed 28 Jan 2026."},{"issue":"2","key":"461_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"461_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"9","key":"461_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"461_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","volume":"31","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail. 2025;31(3):525\u201333.","journal-title":"J Card Fail"},{"issue":"3","key":"461_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","volume":"7","author":"A Masri","year":"2025","unstructured":"Masri A, Bhattacharya P, Medoff B, et al. A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2025;7(3):282\u201393.","journal-title":"JACC CardioOncol"},{"issue":"3","key":"461_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40119-025-00402-y","volume":"14","author":"JD Gillmore","year":"2025","unstructured":"Gillmore JD, Hahn K, Smith JG, et al. Rationale and design of ANTHOLOGY: an ATTR amyloidosis real-world evidence program aiming to address gaps in amyloidosis care. Cardiol Ther. 2025;14(3):477\u201390.","journal-title":"Cardiol Ther"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00461-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:24:30Z","timestamp":1788405870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00461-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00461-9","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marianna Fontana has acted as a consultant, advisor, or speaker for Akcea Therapeutics, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Eidos Therapeutics (a BridgeBio company), Intellia Therapeutics, Ionis Pharmaceuticals, Janssen Global Services, Novo Nordisk, and Pfizer; and has received research grants from Eidos Therapeutics (a BridgeBio company) and Pfizer. Francesco Cappelli reports personal fees from Pfizer, Alnylam Pharmaceuticals, BridgeBio, AstraZeneca, Novo Nordisk, Bristol Myers Squibb, and Bayer. Julian D. Gillmore has received consultancy fees from Pfizer, Ionis Pharmaceuticals, Attralus, Eidos Therapeutics (a BridgeBio company), Alnylam Pharmaceuticals, Alexion Pharmaceuticals, AstraZeneca, and Intellia Therapeutics; and has received institutional research grants from Alnylam Pharmaceuticals, AstraZeneca, Bayer, and Pfizer. Laura Obici reports speaker and consultancy fees from Bayer, BridgeBio, AstraZeneca, Alnylam Pharmaceuticals, Novo Nordisk, Intellia Therapeutics, Medison, Purpose Pharma, and Pfizer. Fabian aus dem Siepen reports advisory honoraria, speaker\u2019s honoraria, and travel grants from Alexion, Alnylam Pharmaceuticals, Bayer, Novo Nordisk, Neurimmune, and Pfizer; and he serves as principal investigator in trials sponsored by Alnylam Pharmaceuticals, AstraZeneca, Bayer, Intellia Therapeutics, Neurimmune, and Novo Nordisk. Philippe Debonnaire reports speaker and consultancy fees from Bayer, Pfizer, AstraZeneca, and Alnylam Pharmaceuticals, and research funding from Pfizer and AstraZeneca. Esther Gonzalez-Lopez reports speaking fees from Pfizer, Eidos Therapeutics (a BridgeBio company), Bayer, AstraZeneca and Alnylam Pharmaceuticals; and consulting fees from Pfizer, Alnylam Pharmaceuticals, Bayer, Akcea, Novo Nordisk, AstraZeneca, and Proclara. Marcel Schulze, Kai Vogtl\u00e4nder, Antonio Ciaccia, and Martin Merz are employees and stockholders of Bayer. Pablo Garcia-Pavia has received speaker fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, Eidos Therapeutics (a BridgeBio company), Intellia Therapeutics, Ionis Pharmaceuticals, Novo Nordisk, and Pfizer; has received consulting fees from Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Attralus, Bayer, BridgeBio, Intellia Therapeutics, Ionis Pharmaceuticals, Pfizer, Neuroimmune, and Novo Nordisk; and has received research\/educational support to his institution from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, Intellia Therapeutics, Novo Nordisk, and Pfizer.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In all countries where reference to an IEC or IRB is required, documented approval from appropriate IECs\/IRBs is obtained for all participating centers prior to study start. All participants are required to provide informed consent before documentation of any data. The sponsor licensed the use of the KCCQ and EQ-5D-5L questionnaires with permission to publish the research results.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}